Table 1 GT-30 baseline patient demographic and clinical characteristics
Characteristics (n = 36) | n (%) |
|---|---|
Median age, years (range) | 66.5 (40–83) |
Sex | |
Female | 11 (30.6%) |
Male | 25 (69.4%) |
Race | |
White | 21 (58.4%) |
Asian | 8 (22.2%) |
Other (Black and Pacific Islander) | 7 (19.4%) |
ECOG performance status | |
0 | 25 (69.4%) |
1 | 11 (30.6%) |
Child–Pugh score A | 36 (100%) |
BCLC stage | |
B | 18 (50.0%) |
C | 18 (50.0%) |
Etiology | |
HBV | 8 (22.2%) |
HCV | 12 (33.3%) |
HBV + HCV | 1 (2.8%) |
Nonviral | 15 (41.7%) |
Prior treatment | |
Sorafenib | 2 (5.6%) |
Sorafenib + lenvatinib | 1 (2.8%) |
Lenvatinib | 33 (91.6%) |
PVI | 7 (19.4%) |
Wnt/β-catenin mutation | 10 (27.8%) |
Baseline AFP, ng ml−1 | |
≥400 | 8 (22.2%) |
<400 | 28 (77.8%) |
Targetable neoantigensa | |
≤20 | 10 (27.8%) |
21–40 | 16 (44.4%) |
41–67 | 10 (27.8%) |
